Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PD1-Vaxx in Operable MSI High Colorectal Cancer
NCT06692959Phase 2Terminated
- Sponsor
- University of Southampton
- Start
- Jun 2025
- Primary completion
- Jun 2026
- Modality
- Prophylactic Vaccines, Peptide-based Cancer Vaccines
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of pd1-vaxx in colorectal cancer (CRC), sponsored by University of Southampton. Primary endpoint: Major Pathological Response. Started Jun 2025; status: terminated.
02
Drugs
pd1-vaxx
03
Conditions
colorectal cancer (CRC)
Beyond the preview
Go deeper on NCT06692959.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06692959.